FDA places partial clinical hold on Biohaven's epilepsy drug
The FDA has placed a partial clinical hold pausing enrollment in the RISE-2 trial of opakalim (BHV-7000), an investigational potassium-channel activator for focal epilepsy.
News
Publications
Vision AI guides surgical pathology decisions across 3,000 patients in the operating room
Researchers trained a computational pathology foundation model called CRISP on more than 100,000 frozen-tissue sections from 10 medical centers, testing it on 15,000 retrospective slides across 14 tumor types.
Ensemble learning combines pathology foundation models to predict cancer therapy response
Researchers developed ELF, an ensemble learning framework that unifies slide-level representations from five distinct pretrained pathology foundation models.
Self-supervised AI maps four-dimensional mitochondrial dynamics from light-sheet microscopy
Scientists developed MitoSpace, a self-supervised deep learning model trained on terabytes of time-lapse, three-dimensional lattice light-sheet imaging of mitochondria under various chemical and biological perturbations.
Preprints
Neural network picks out rare proteins in electron microscope mixtures
A deep-learning classifier named CryoConvNeXt successfully identifies low-abundance protein particles in heterogeneous cryo-electron microscopy samples down to 1:16 dilution ratios.
Deep learning maps contact points between hepatitis B capsid and envelope
Virologists used mutation-driven deep learning alongside evolutionary sequence analysis to map binding sites between the hepatitis B capsid protein and its large envelope protein LHBs.
Engineered natural ligand boosts cell therapy against cancer target CD70
Researchers combined deep learning and molecular dynamics simulations to re-engineer CD27, the natural binding partner of the pan-cancer target CD70, for use in chimeric antigen receptor (CAR) T-cell therapy.
AI pipeline chains single-cell models to screen drug combinations
Computational biologists introduced PHAROS, an algorithmic framework that chains predictions from existing single-cell perturbation models to simulate and search for synergistic two-drug combinations.